Novo Nordisk Sees Retail Buying Despite Wall Street Cuts

Mitrade
Updated
coverImg
Source: DepositPhotos

Insights – Shares of leading weight-loss drugmaker Novo Nordisk plunged after disappointing results from its latest weight-loss drug trial. Despite analysts slashing their price targets, retail investors flooded into the stock with massive buy-the-dip activity.  


According to data from Vanda Research, retail inflows into Novo Nordisk surged 32-fold on Friday, December 20. The single-day net inflow jumped from $490,000 the previous day to $15.6 million.  


Marco Iachini, Senior Vice President at Vanda Research, noted that retail investors tend to buy the dip, particularly in popular stocks, and added that they would continue doing so until the strategy ceased to be effective.


Novo Nordisk’s December 20 trial results revealed that its next-generation weight-loss drug, CagriSema, achieved only a 22.7% weight loss effect after eight weeks of treatment, falling short of the market expectation of 25%.  


The company’s previous flagship weight-loss drug, Wegovy, had set high standards, and Novo Nordisk had hoped CagriSema would outperform its main competitor, Eli Lilly’s (LLY.US) Zepbound. However, the underwhelming trial results sent Novo Nordisk shares tumbling 17.83% on the day, while Eli Lilly’s stock ended a multi-day decline, rising 1.35%.  


Following the trial results, Wall Street analysts sharply lowered their price targets for Novo Nordisk.BMO Capital** cut its target from $156 to $105.  TD Cowen** reduced its target from $155 to $105.  Jefferies downgraded its target to $81.50 and maintained a "Sell" rating.  


As of the latest close, Novo Nordisk shares traded at $87.37, representing a year-to-date decline of 15.54%.  




* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
Tesla’s market share in China dropped to 4%Tesla is bleeding market share in China while Elon Musk’s influence there is evaporating.
Author  Cryptopolitan
23 hours ago
Tesla is bleeding market share in China while Elon Musk’s influence there is evaporating.
placeholder
Jeff Bezos sold nearly 3 million Amazon shares for $665.8 million in early JulyJeff Bezos has sold nearly three million shares of Amazon in the first two days of July, offloading a total of $665.8 million.
Author  Cryptopolitan
Yesterday 03: 43
Jeff Bezos has sold nearly three million shares of Amazon in the first two days of July, offloading a total of $665.8 million.
placeholder
Global markets aren’t buying Trump’s tariff threats this timeGlobal stocks are breaking records in 2025 while Donald Trump keeps yelling tariffs from the White House.
Author  Cryptopolitan
Yesterday 02: 57
Global stocks are breaking records in 2025 while Donald Trump keeps yelling tariffs from the White House.
placeholder
Dow Jones Futures attempt to recover losses as Trump delays tariff implementationDow Jones Futures move sideways ahead of the opening on Tuesday, trading around 44,680, up by 0.01%.
Author  FXStreet
Jul 08, Tue
Dow Jones Futures move sideways ahead of the opening on Tuesday, trading around 44,680, up by 0.01%.
placeholder
Citigroup Revs Up the Engine: Raises NVIDIA Target to $190, Eyes $4 Trillion MarketCitigroup has recently raised its price target for NVIDIA (NVIDIA.US) from its previous level to $190 per share, suggesting roughly 15% upside from Thursday’s closing price.
Author  TradingKey
Jul 08, Tue
Citigroup has recently raised its price target for NVIDIA (NVIDIA.US) from its previous level to $190 per share, suggesting roughly 15% upside from Thursday’s closing price.